Biocon informed the bourses that the company along with Mylan has launch Ogivri (trastuzumab), a biosimilar to Herceptin1, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) in Australia.